Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (423)	2/16/2005 5:26:46 PM
From: Sam Citron	Respond to of 946

I don't know about any hirsute Russians, but when stocks and options diverge, I've noticed the options usually have it right. Sam

To: Icebrg who wrote (423)	2/22/2005 8:59:25 PM
From: tuck	Read Replies (1) \| Respond to of 946

Cross posting a couple of CTIC related posts from the Valuation thread . . . Miljenko has expressed concerns about the outcome of the trial based on PK/PD data that he can't find the notes for anymore. He said too much was excreted in urine, i.e. the formulation was too stable: Message 20932102 Those concerns might be addressed in part in this dig by Zeta: Message 21071274 Thoughts from the thread? Lightened position slightly, so that a disaster for XYOTAX will be breakeven (and then might load because of Pixantrone) for me, but still got enough to make some change if XYOTAX succeeds. In other words, still looking for clues. Cheers, Tuck